Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
Ranibizumab for Neovascular Age-Related Macular Degeneration
20064.6k citationsPhilip J. Rosenfeld, David M. Brown et al.New England Journal of Medicineprofile →
A cellular DNA-binding protein that activates eukaryotic transcription and DNA replication
1987998 citationsPhilip J. Rosenfeld et al.profile →
Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt's macular dystrophy: follow-up of two open-label phase 1/2 studies
2014926 citationsPhilip J. Rosenfeld, Ninel Z. Gregori et al.profile →
An Optical Coherence Tomography-Guided, Variable Dosing Regimen with Intravitreal Ranibizumab (Lucentis) for Neovascular Age-related Macular Degeneration
2007802 citationsAnne E. Fung, Geeta A. Lalwani et al.American Journal of Ophthalmologyprofile →
Optical Coherence Tomography Findings After an Intravitreal Injection of Bevacizumab (Avastin®) for Neovascular Age-Related Macular Degeneration
2005724 citationsPhilip J. Rosenfeld, Andrew A. Moshfeghi et al.Ophthalmic surgery, lasers & imaging retinaprofile →
A Variable-dosing Regimen with Intravitreal Ranibizumab for Neovascular Age-related Macular Degeneration: Year 2 of the PrONTO Study
2009719 citationsGeeta A. Lalwani, Philip J. Rosenfeld et al.American Journal of Ophthalmologyprofile →
Optical coherence tomography angiography: A comprehensive review of current methods and clinical applications
2017703 citationsAmir H. Kashani, Fang Zheng et al.profile →
Systemic Bevacizumab (Avastin) Therapy for Neovascular Age-Related Macular DegenerationTwelve-Week Results of an Uncontrolled Open-Label Clinical Study
2005530 citationsPhilip J. Rosenfeld et al.Ophthalmologyprofile →
The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide
2006446 citationsAnne E. Fung, Philip J. Rosenfeld et al.profile →
NOVEL METHOD FOR ANALYZING SNELLEN VISUAL ACUITY MEASUREMENTS
2010405 citationsNinel Z. Gregori, William J. Feuer et al.profile →
Vision Loss after Intravitreal Injection of Autologous “Stem Cells” for AMD
2017331 citationsThomas A. Albini, Justin H. Townsend et al.New England Journal of Medicineprofile →
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late)
cites ·
hero ref
Countries citing papers authored by Philip J. Rosenfeld
Since
Specialization
Citations
This map shows the geographic impact of Philip J. Rosenfeld's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philip J. Rosenfeld with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philip J. Rosenfeld more than expected).
Fields of papers citing papers by Philip J. Rosenfeld
This network shows the impact of papers produced by Philip J. Rosenfeld. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philip J. Rosenfeld. The network helps show where Philip J. Rosenfeld may publish in the future.
Co-authorship network of co-authors of Philip J. Rosenfeld
This figure shows the co-authorship network connecting the top 25 collaborators of Philip J. Rosenfeld.
A scholar is included among the top collaborators of Philip J. Rosenfeld based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Philip J. Rosenfeld. Philip J. Rosenfeld is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Gregori, Giovanni, Fang Zheng, Qinqin Zhang, et al.. (2019). Age-Dependent Changes in the Macular Choriocapillaris of Normal Eyes Imaged with Swept-Source OCT Angiography.. Investigative Ophthalmology & Visual Science. 60(9). 3282–3282.8 indexed citations
10.
Gregori, Giovanni, Philip J. Rosenfeld, Cancan Lyu, et al.. (2019). A method for automated choroidal-scleral interface segmentation in optical coherence tomography. Investigative Ophthalmology & Visual Science. 60(9). 143–143.2 indexed citations
Wang, Ruikang K., Mitchell A. Kirby, Chenxi Li, et al.. (2017). An explanation for why choroidal blood vessels appear dark on clinical OCT images. Investigative Ophthalmology & Visual Science. 58(8). 4754–4754.5 indexed citations
Ploner, Stefan B., Eric M. Moult, Nadia K. Waheed, et al.. (2016). Toward quantitative OCT angiography: visualizing flow impairment using variable interscan time analysis (VISTA). Investigative Ophthalmology & Visual Science. 57(12).4 indexed citations
15.
Flynn, Harry W., Ninel Z. Gregori, Andrew A. Moshfeghi, et al.. (2015). Current Endophthalmitis Incidence Rates After Intravitreal Anti-VEGF Injections and Outcomes of Treatment. Investigative Ophthalmology & Visual Science. 56(7). 4193–4193.1 indexed citations
Rosenfeld, Philip J., et al.. (2008). Lesion Characteristics in Ranibizumab (LUCENTIS®) Treated Patients With a Visual Acuity (VA) Gain or Loss in the MARINA and ANCHOR Trials for Wet Age-Related Macular Degeneration (AMD). Investigative Ophthalmology & Visual Science. 49(13). 329–329.1 indexed citations
18.
Fung, Anne E., Geeta A. Lalwani, Stephan Michels, et al.. (2007). Characteristics of Patients Losing Vision at Year 1 of the PrONTO Study. Investigative Ophthalmology & Visual Science. 48(13). 4579–4579.1 indexed citations
19.
Rosenfeld, Philip J., David M. Brown, Jeffrey S. Heier, et al.. (2006). Ranibizumab for Neovascular Age-Related Macular Degeneration. New England Journal of Medicine. 355(14). 1419–1431.4598 indexed citations breakdown →
20.
Slakter, Jason S. & Philip J. Rosenfeld. (2003). Verteporfin With Altered (Delayed) Light in Occult CNV (VALIO) – Results of a Phase II Controlled Clinical Trial. Investigative Ophthalmology & Visual Science. 44(13). 1101–1101.2 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.